MiMedx to Present at the 28th Annual Piper Jaffray Healthcare Conference

Friday, November 18, 2016 General News J E 4

MARIETTA, Ga., Nov. 18, 2016 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading regenerative medicine company utilizing human amniotic tissue and patent-protected processes to develop and market advanced products and therapies for the Wound Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and Dental sectors of healthcare, announced today that it will participate in the 28th Annual Piper Jaffray Healthcare Conference in New York, NY.  Parker H. "Pete" Petit, Chairman and CEO, Michael J. Senken, Chief Financial Officer, Christopher M. Cashman, EVP and Chief Commercialization Officer, and Mark Landy, Vice President, Strategic Initiatives, are scheduled to participate on Tuesday, November 29, 2016 at 8:30 a.m. eastern time, at the Lotte New York Palace.  A webcast of this presentation will be available on the Company's website,

About MiMedxMiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other human birth tissues, such as amniotic fluid, umbilical cord and placental collagen, and human skin and bone.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself.  We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization.  MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

To view the original version on PR Newswire, visit:

SOURCE MiMedx Group, Inc.



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Dehaier Medical Changed its Name to Lianluo Smart
Astellas Extends Commitment with the Canadian Urol...